Project description
Innovative software-aided microscopy for Lyme disease testing
Lyme borreliosis is the most common zoonotic disease in Europe. If not diagnosed and treated early causes severe and potentially persisting symptoms representing a heavy burden on the European healthcare system. However, existing serological tests for Lyme disease are highly unreliable in the early stages. The patented DualDur reagent and method is based on direct detection of the bacteria and does not rely on the immune response, enabling a more reliable early diagnosis, but is a supplementary testing method at research institutes. The EU-funded DualDur project will validate an innovative testing procedure based on software-aided microscopy that improves time-to-result by 10 times and needs lesser personnel, allowing the widespread application of DualDur.
Objective
Lyme borreliosis (LB) is the most common zoonotic disease in Europe with 650-850,000 estimated cases. Currently used serological tests for Lyme disease are highly unreliable in early stages of the infection, showing 17-40% sensitivity. If the disease is not diagnosed and treated early on; the infection often spreads to joints, the nervous system, and the heart causing severe and potentially persisting symptoms. Late stage, disseminated LB is a heavy burden on the patients in terms of quality of life and direct and indirect costs. It is also a significant burden on the European healthcare system: the majority of the €1 billion annual cost of the disease is associated with late stage LB. Our patented DualDur reagent and method enables a more reliable early diagnosis of Lyme disease than currently used serological methods, as it is based on direct detection of the bacteria and does not rely on the immune response. So far used as a supplementary testing method mainly at research institutes, in the present project we aim to validate a novel testing procedure based on software-aided microscopy. This will allow the wide-spread application of DualDur, as it improves time-to-result by 10 times, and decreases personnel need compared to our current procedure. Our improved reagent and software-aided testing enables us to provide the DualDur tests all over Europe through partnerships with medical laboratories. More reliable early diagnosis of Lyme disease will reduce the number of later stage cases significantly. This in turn will improve the quality of life of patients and reduce the financial burden of the disease, saving approximately € 330 million on healthcare costs in the first 5 years already. DualDur testing targets the €400 million European Lyme diagnostic market. We will be able to capture 5,1% of this growing market by 2024; representing an annual testing revenue of €23 million at our laboratory partners; and an annual turnover of close to €6 million to our company.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences neurobiology
- natural sciences biological sciences microbiology bacteriology
- medical and health sciences basic medicine immunology
- engineering and technology medical engineering medical laboratory technology diagnostic technologies
- medical and health sciences health sciences public health epidemiology zoonosis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2011 BUDAKALASZ
Hungary
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.